140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations

Park KTan E.-HZhang LHirsh VO'Byrne KBoyer MCHIH-HSIN YANGMok TKim MPaz-Ares L.2020-05-262020-05-2620161556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037604373&doi=10.1016%2fS1556-0864%2816%2930250-7&partnerID=40&md5=44f300d7099cc9c659bd825642f4ab3ahttps://scholars.lib.ntu.edu.tw/handle/123456789/494985[SDGs]SDG3afatinib; alanine aminotransferase; epidermal growth factor receptor; gefitinib; acne; advanced cancer; alanine aminotransferase blood level; Article; Asian; brain metastasis; controlled study; diarrhea; drug efficacy; drug response; drug safety; drug treatment failure; drug withdrawal; EGFR gene; female; gene deletion; gene mutation; human; major clinical study; male; non small cell lung cancer; open study; overall survival; phase 2 clinical trial; priority journal; progression free survival; prospective study; randomized controlled trial; rash; side effect; tumor volume140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutationsjournal article10.1016/S1556-0864(16)30250-72-s2.0-85037604373